首页 > 最新文献

Archives of hematology and blood diseases最新文献

英文 中文
The Role of Magnesium as Immunomodulator and Mediator between Immune and Colon Cancer Cells 镁在免疫和结肠癌细胞间的免疫调节剂和中介作用
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0202002
C. Leibovitch, Esther Ganelin Cohen, M. Djaldetti, H. Bessler
{"title":"The Role of Magnesium as Immunomodulator and Mediator between Immune and Colon Cancer Cells","authors":"C. Leibovitch, Esther Ganelin Cohen, M. Djaldetti, H. Bessler","doi":"10.22259/2639-3581.0202002","DOIUrl":"https://doi.org/10.22259/2639-3581.0202002","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Day-Per-Day Maintenance and Six Sigma of the Landwind LW D3600 Hematological Analyzer: Clinical Aspects and Quality Verification 陆风LW D3600血液分析仪的日常维护和六西格玛:临床方面和质量验证
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0201004
Jeel Moya-Salazar
{"title":"Day-Per-Day Maintenance and Six Sigma of the Landwind LW D3600 Hematological Analyzer: Clinical Aspects and Quality Verification","authors":"Jeel Moya-Salazar","doi":"10.22259/2639-3581.0201004","DOIUrl":"https://doi.org/10.22259/2639-3581.0201004","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Heavy Metal Bioaccumulation, Urinary Microalbumin and Some Haematological Variables among Artisans in Jos Metropolis 乔斯市工匠重金属生物积累、尿微量白蛋白及一些血液学变量
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0201005
Bot Yakubu S, Nwanjo Harrison U, Nwosu Dennis C, Lugos Moses D
{"title":"Heavy Metal Bioaccumulation, Urinary Microalbumin and Some Haematological Variables among Artisans in Jos Metropolis","authors":"Bot Yakubu S, Nwanjo Harrison U, Nwosu Dennis C, Lugos Moses D","doi":"10.22259/2639-3581.0201005","DOIUrl":"https://doi.org/10.22259/2639-3581.0201005","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal Genetics, Health and Hematological Profile of Pregnant Women in Madhya Pradesh, India 印度中央邦孕妇的母体遗传、健康和血液学概况
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0202003
R. Balgir
{"title":"Maternal Genetics, Health and Hematological Profile of Pregnant Women in Madhya Pradesh, India","authors":"R. Balgir","doi":"10.22259/2639-3581.0202003","DOIUrl":"https://doi.org/10.22259/2639-3581.0202003","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Large B Cell Lymphoma in the Tibia of an Old Individual Relapsing at an Uncommon Location 老年人胫骨原发性大B细胞淋巴瘤在不常见部位复发
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0202001
Meir Djaldetti M.D
{"title":"Primary Large B Cell Lymphoma in the Tibia of an Old Individual Relapsing at an Uncommon Location","authors":"Meir Djaldetti M.D","doi":"10.22259/2639-3581.0202001","DOIUrl":"https://doi.org/10.22259/2639-3581.0202001","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amino Acids in the Diagnosis and Treatment of Liver Damage (Review) 氨基酸在肝损伤诊断和治疗中的应用(综述)
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0202005
I. I. Nefyodov, A. J. Karakosh, M. A. Alufaini, P. Karavay, N. Karavay
{"title":"Amino Acids in the Diagnosis and Treatment of Liver Damage (Review)","authors":"I. I. Nefyodov, A. J. Karakosh, M. A. Alufaini, P. Karavay, N. Karavay","doi":"10.22259/2639-3581.0202005","DOIUrl":"https://doi.org/10.22259/2639-3581.0202005","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). 自体造血干细胞移植(aHSCT)改善原发性系统性淀粉样变性(AL淀粉样变性)患者的治疗相关死亡率
Archives of hematology and blood diseases
Pub Date : 2019-01-01
Akshata Pandit, Lai Wei, Luis Bustamante, Patrick Elder, William B S Falk, Megan Sell, Ashley Rosko, Don M Benson, Steven M Devine, Craig C Hofmeister, Yvonne A Efebera

To date, there is no standard of care for patients with newly diagnosed Primary (AL) amyloidosis. Autologous hematopoietic stem cell transplant (aHSCT) is a reasonable option, but has been limited in its use due to increase in treatment-related mortality (TRM). We retrospectively analyzed the outcomes of 42 newly diagnosed consecutive AL amyloidosis patients transplanted at our center. The median age at aHSCT was 57.5 (range 26-71). Twenty one (50%) had involvement of at least two organs and 40 (97%) patients had cardiac stage I or II. Patients received high dose Melphalan 140(n=4) or 200(n=38) mg/m2. Median times to neutrophil and platelet engraftments were 12 and 18 days, respectively. Three months hematologic response were complete response in 21 patients (50%), very good partial response in 4 (10%), partial response in 5 (12%) and Minimal/Stable disease in 6(15%). The respective 1, 3, and 5 year progression-free survival were 79%, 67% and 57%, and overall survival from Transplant 81%, 73% and 66%. Day 100 and 1 year TRM were 4.8% and 7.1% respectively. Our results show that aHSCT is a safe and reasonable option for patients with AL amyloidosis. Day 100 and 1 year TRM compares favorably to multiple myeloma patients undergoing aHSCT.

到目前为止，对于新诊断的原发性(AL)淀粉样变性患者没有标准的护理。自体造血干细胞移植(aHSCT)是一种合理的选择，但由于治疗相关死亡率(TRM)的增加，其使用受到限制。我们回顾性分析了42例新诊断的连续AL淀粉样变性患者在本中心移植的结果。aHSCT的中位年龄为57.5岁(范围26-71岁)。21例(50%)患者至少有两个器官受累，40例(97%)患者有心脏I期或II期。患者接受高剂量美法兰140(n=4)或200(n=38) mg/m2。中性粒细胞和血小板植入的中位时间分别为12天和18天。3个月的血液学反应为21例(50%)完全缓解，4例(10%)非常好部分缓解，5例(12%)部分缓解，6例(15%)病情轻微/稳定。1年、3年和5年的无进展生存率分别为79%、67%和57%，移植总生存率分别为81%、73%和66%。第100天和第1年TRM分别为4.8%和7.1%。我们的研究结果表明aHSCT是AL淀粉样变性患者安全合理的选择。与接受aHSCT的多发性骨髓瘤患者相比，第100天和第1年的TRM更有利。
{"title":"Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).","authors":"Akshata Pandit,&nbsp;Lai Wei,&nbsp;Luis Bustamante,&nbsp;Patrick Elder,&nbsp;William B S Falk,&nbsp;Megan Sell,&nbsp;Ashley Rosko,&nbsp;Don M Benson,&nbsp;Steven M Devine,&nbsp;Craig C Hofmeister,&nbsp;Yvonne A Efebera","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To date, there is no standard of care for patients with newly diagnosed Primary (AL) amyloidosis. Autologous hematopoietic stem cell transplant (aHSCT) is a reasonable option, but has been limited in its use due to increase in treatment-related mortality (TRM). We retrospectively analyzed the outcomes of 42 newly diagnosed consecutive AL amyloidosis patients transplanted at our center. The median age at aHSCT was 57.5 (range 26-71). Twenty one (50%) had involvement of at least two organs and 40 (97%) patients had cardiac stage I or II. Patients received high dose Melphalan 140(n=4) or 200(n=38) mg/m<sup>2</sup>. Median times to neutrophil and platelet engraftments were 12 and 18 days, respectively. Three months hematologic response were complete response in 21 patients (50%), very good partial response in 4 (10%), partial response in 5 (12%) and Minimal/Stable disease in 6(15%). The respective 1, 3, and 5 year progression-free survival were 79%, 67% and 57%, and overall survival from Transplant 81%, 73% and 66%. Day 100 and 1 year TRM were 4.8% and 7.1% respectively. Our results show that aHSCT is a safe and reasonable option for patients with AL amyloidosis. Day 100 and 1 year TRM compares favorably to multiple myeloma patients undergoing aHSCT.</p>","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"2 1","pages":"12-18"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734359/pdf/nihms-1573589.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39804557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Screening of Blood Donors for G6PD Deficiency and Hemoglobinopathies a Necessity for Transfusion Medicine in India? 对献血者进行G6PD缺乏症和血红蛋白病筛查是印度输血医学的必要条件吗?
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0202004
R. Balgir
{"title":"Is Screening of Blood Donors for G6PD Deficiency and Hemoglobinopathies a Necessity for Transfusion Medicine in India?","authors":"R. Balgir","doi":"10.22259/2639-3581.0202004","DOIUrl":"https://doi.org/10.22259/2639-3581.0202004","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients 原发性IO患者缺铁治疗期间Lp-PLA2活性
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0201002
Tetzlaff Walter F, Martin Maximiliano E, Botta Eliana E, Saez Maria S, Ferraro Florencia M, Boero Laura E, Sorroche Patricia B, Arbelbide Jorge, Brites Fernando, Merono Tomas
{"title":"Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients","authors":"Tetzlaff Walter F, Martin Maximiliano E, Botta Eliana E, Saez Maria S, Ferraro Florencia M, Boero Laura E, Sorroche Patricia B, Arbelbide Jorge, Brites Fernando, Merono Tomas","doi":"10.22259/2639-3581.0201002","DOIUrl":"https://doi.org/10.22259/2639-3581.0201002","url":null,"abstract":"","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). 自体造血干细胞移植(aHSCT)改善原发性系统性淀粉样变性(AL淀粉样变性)患者的治疗相关死亡率
Archives of hematology and blood diseases
Pub Date : 2019-01-01 DOI: 10.22259/2639-3581.0201003
A. Pandit, Lai Wei, Luis Bustamante, P. Elder, W. Falk, M. Sell, A. Rosko, D. Benson, S. Devine, C. Hofmeister, Y. Efebera
To date, there is no standard of care for patients with newly diagnosed Primary (AL) amyloidosis. Autologous hematopoietic stem cell transplant (aHSCT) is a reasonable option, but has been limited in its use due to increase in treatment-related mortality (TRM). We retrospectively analyzed the outcomes of 42 newly diagnosed consecutive AL amyloidosis patients transplanted at our center. The median age at aHSCT was 57.5 (range 26-71). Twenty one (50%) had involvement of at least two organs and 40 (97%) patients had cardiac stage I or II. Patients received high dose Melphalan 140(n=4) or 200(n=38) mg/m2. Median times to neutrophil and platelet engraftments were 12 and 18 days, respectively. Three months hematologic response were complete response in 21 patients (50%), very good partial response in 4 (10%), partial response in 5 (12%) and Minimal/Stable disease in 6(15%). The respective 1, 3, and 5 year progression-free survival were 79%, 67% and 57%, and overall survival from Transplant 81%, 73% and 66%. Day 100 and 1 year TRM were 4.8% and 7.1% respectively. Our results show that aHSCT is a safe and reasonable option for patients with AL amyloidosis. Day 100 and 1 year TRM compares favorably to multiple myeloma patients undergoing aHSCT.
到目前为止，对于新诊断的原发性(AL)淀粉样变性患者没有标准的护理。自体造血干细胞移植(aHSCT)是一种合理的选择，但由于治疗相关死亡率(TRM)的增加，其使用受到限制。我们回顾性分析了42例新诊断的连续AL淀粉样变性患者在本中心移植的结果。aHSCT的中位年龄为57.5岁(范围26-71岁)。21例(50%)患者至少有两个器官受累，40例(97%)患者有心脏I期或II期。患者接受高剂量美法兰140(n=4)或200(n=38) mg/m2。中性粒细胞和血小板植入的中位时间分别为12天和18天。3个月的血液学反应为21例(50%)完全缓解，4例(10%)非常好部分缓解，5例(12%)部分缓解，6例(15%)病情轻微/稳定。1年、3年和5年的无进展生存率分别为79%、67%和57%，移植总生存率分别为81%、73%和66%。第100天和第1年TRM分别为4.8%和7.1%。我们的研究结果表明aHSCT是AL淀粉样变性患者安全合理的选择。与接受aHSCT的多发性骨髓瘤患者相比，第100天和第1年的TRM更有利。
{"title":"Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).","authors":"A. Pandit, Lai Wei, Luis Bustamante, P. Elder, W. Falk, M. Sell, A. Rosko, D. Benson, S. Devine, C. Hofmeister, Y. Efebera","doi":"10.22259/2639-3581.0201003","DOIUrl":"https://doi.org/10.22259/2639-3581.0201003","url":null,"abstract":"To date, there is no standard of care for patients with newly diagnosed Primary (AL) amyloidosis. Autologous hematopoietic stem cell transplant (aHSCT) is a reasonable option, but has been limited in its use due to increase in treatment-related mortality (TRM). We retrospectively analyzed the outcomes of 42 newly diagnosed consecutive AL amyloidosis patients transplanted at our center. The median age at aHSCT was 57.5 (range 26-71). Twenty one (50%) had involvement of at least two organs and 40 (97%) patients had cardiac stage I or II. Patients received high dose Melphalan 140(n=4) or 200(n=38) mg/m2. Median times to neutrophil and platelet engraftments were 12 and 18 days, respectively. Three months hematologic response were complete response in 21 patients (50%), very good partial response in 4 (10%), partial response in 5 (12%) and Minimal/Stable disease in 6(15%). The respective 1, 3, and 5 year progression-free survival were 79%, 67% and 57%, and overall survival from Transplant 81%, 73% and 66%. Day 100 and 1 year TRM were 4.8% and 7.1% respectively. Our results show that aHSCT is a safe and reasonable option for patients with AL amyloidosis. Day 100 and 1 year TRM compares favorably to multiple myeloma patients undergoing aHSCT.","PeriodicalId":93414,"journal":{"name":"Archives of hematology and blood diseases","volume":"66 1","pages":"12-18"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68287604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Archives of hematology and blood diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1